Previously, we have utilized MDC/CCL22 to induce a Th2-type immune response to DNA vaccine encoding tumor or viral antigens and generated high titers of therapeutic antibody [29], [30], suggesting that this may also enable us to develop a safe and potent AD vaccine. This evidence concerns the gene CCL22 and Alzheimer disease.